Navigation Links
Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
Date:10/1/2008

ia when a middle of the night awakening is followed by difficulty returning to sleep. Phase 3 clinical trials have been completed for Intermezzo(R) and Transcept submitted an NDA to the FDA via the 505(b)(2) pathway on September 30, 2008.

For further information, please visit the company's website at: http://www.transcept.com.

About Novacea

Novacea, Inc. is a biopharmaceutical company that had been focused on in-licensing, developing and commercializing novel cancer therapies. Novacea has two product candidates, including Asentar(TM), which had been in a Phase 3 clinical trial for androgen-independent prostate cancer, and AQ4N, a hypoxia-activated prodrug. There are currently no clinical trials planned or underway for either candidate.

Safe Harbor

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Transcept and Novacea disclaim any intent or obligation to update these forward-looking statements, and claim the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the expected timing of closing the merger, the expected cash balance of the combined entity as of the closing, the sufficiency of post closing cash to fund development of Intermezzo(R) through planned commercialization and the potential markets and expected benefits of Transcept product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, failure of Novacea stockholders to approve the merger; Novacea or Transcept inability to satisfy the conditions of the merger, or that the merger is otherwise delayed or ultimately not consummated; the rates of use of Transcept and Novacea cash and cash equivalents prior to the clos
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
2. Critical Pharmaceuticals Enter Sustained Release hGH Arena
3. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
4. Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4
5. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
6. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
7. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
8. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
9. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
10. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
11. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014  Array BioPharma Inc. (Nasdaq:   ARRY) ... quarter and full year of fiscal 2014 ... those results on Tuesday, August 12, 2014.  ... Michael Carruthers , Chief Financial Officer will ... 2014Time:9:00 a.m. Eastern TimeToll-Free:(800) 708-4540Toll:(847) 619-6397Pass Code: ...
(Date:7/28/2014)... July 28, 2014  Syneron Medical Ltd. (NASDAQ: ... announced today that its new PicoWay® device has received ... and colors and pigmented lesions on any skin type. ... with 532nm and 1064nm wavelengths, which utilizes Syneron,s proprietary ... pulses which are trillionths of a second, known as ...
(Date:7/28/2014)... -- ResMed (NYSE: RMD ), an innovator and ... breathing and other chronic respiratory conditions, has won a ... Taiwanese medical device manufacturer APEX Medical Corp. (APEX), prohibiting ... and 220 masks.  The judgment was entered by the ... is appealable, and applies throughout Germany.  ...
Breaking Medicine Technology:Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe 2
... April 17, 2007,/PRNewswire-FirstCall/ -- Cell Genesys, Inc. ... conducted Phase 2 clinical trials,of GVAX immunotherapy ... patients with advanced prostate cancer from these,studies ... responses to a broad array of prostate ...
... A 9-month, randomized,double-blind, parallel-group Phase II study of ... given daily to the currently,approved COPAXONE(R) 20 mg ... disease activity as measured by magnetic,resonance images (MRI) ... mg experienced a reduced mean on-trial relapse rate,of ...
Cached Medicine Technology:Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces,a Broad, Patient-Specific Antibody Response 2Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces,a Broad, Patient-Specific Antibody Response 3Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces,a Broad, Patient-Specific Antibody Response 4Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 2Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 3Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 4Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 5
(Date:7/28/2014)... to treat severe chronic migraine headaches led to significant ... in patients treated at Massachusetts General Hospital (MGH). ... Surgery report that more than half of 35 patients ... had headaches associated with compression of craniofacial nerves ... team,s paper has received advance online publication in the ...
(Date:7/28/2014)... Glutamine is the most abundant single amino ... conditionally essential during times when the body undergoes large ... Immune System Support. , Having a heavy work out ... with additional glutamine may be advantageous. Glutamine supplementation may ... digestion and immune system function. Stress on the body ...
(Date:7/28/2014)... 2014 (HealthDay News) --,The more chronic medical conditions people ... may be, a new study claims. Since ... issues, scientists at Johns Hopkins Bloomberg School of Public ... why gains in life expectancy are slowing in the ... as diabetes, kidney disease and heart failure is now ...
(Date:7/28/2014)... divide unless there is enough oxygen present to support ... types circumvent this rule. Researchers at The Johns Hopkins ... cells, warning signals, enabling cancers to continue to divide ... the researchers found that lysosomes the cell,s protein ... also uncovered new evidence that certain drugs can halt ...
(Date:7/28/2014)... NY (PRWEB) July 28, 2014 The ... organization that has donated more than 200,000 books to ... 2001, announces the launch of Brooke’s Cooks, a new ... while encouraging healthy living among at-risk children and their ... will include a series of nutrition information workshops, cooking ...
Breaking Medicine News(10 mins):Health News:Non-endoscopic migraine surgery provides significant symptom relief 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 3Health News:Chronic Medical Conditions Can Shorten Seniors' Lives: Study 2Health News:Cell's recycling center implicated in division decisions 2Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 2Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 3Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 4
... 3 Endologix, Inc. (Nasdaq: ELGX ), developer of minimally ... and Chief Executive Officer, is scheduled to present at three upcoming ... Adams 3rd Annual Cardiovascular Conference at the Nikko Hotel in San ... Event: Canaccord Adams 3rd Annual Cardiovascular Conference, ...
... after the attacks, study shows , TUESDAY, Nov. 3 (HealthDay ... asthma rates twice that of the general population, a new ... and volunteers who had spent time at Ground Zero reported ... about 4 percent of the general population. The rate of ...
... , TUESDAY, Nov. 3 (HealthDay News) -- Experts have ... healthier than regular cigarettes, and new research suggests they ... less likely to quit, even those who switch specifically ... "switching to [,light, cigarettes] for any reason ...
... NBTY, Inc. (NYSE: NTY ) ( www.NBTY.com ... announced it will web cast a conference call to review fiscal ... ), on Monday, November 9, 2009 at 4:30 PM (ET). ... results will be issued at 4:00 PM (ET) that day. , ...
... COLUMBUS, Ohio, Nov. 3 National claims and risk management ... approach to claims management that ensures medical experts are involved ... company notes that the goal of the new service is ... the duration and overall cost of workers, comp claims. Avizent ...
... ... of the Health IT Standards Committee hearing held in Washington, D.C. last week, which was ... ... Orion Health Inc. endorses and commends the efforts of the Health IT Standards Committee ...
Cached Medicine News:Health News:Endologix to Present at Three Upcoming Conferences 2Health News:World Trade Center Workers Twice as Likely to Have Asthma 2Health News:World Trade Center Workers Twice as Likely to Have Asthma 3Health News:Switch to 'Light' Cigarettes Makes Quitting Tougher 2Health News:Switch to 'Light' Cigarettes Makes Quitting Tougher 3Health News:NBTY to Web Cast Fiscal Fourth Quarter Conference Call 2Health News:Avizent's New TeamCOMP Approach Helps Ensure Lower Workers' Comp Costs and Faster Claims Resolution 2Health News:Orion Health™ Participates in Health IT Standards Committee Hearing 2Health News:Orion Health™ Participates in Health IT Standards Committee Hearing 3Health News:Orion Health™ Participates in Health IT Standards Committee Hearing 4
... The StatusFirst CHF test ... anti-NT-proBNP antibody/streptavidin solid-phase chromatographic ... a sample has been ... well, the StatusFirst CHF ...
... practices that need an ... Burdick Vision,Premier Holter System ... The Vision Premier system,adds ... a,more comprehensive list of ...
... EK-10 single-channel,electrocardiograph features a ... keypad. It provides the,necessary ... quick and,accurate diagnosis. The ... a built in handle ...
... contrast levels (high, 9.5 % and 6%) of ... is designed to detect very subtle changes in ... or due to refractive surgery. The upper two ... and acuity levels as the lower two rows; ...
Medicine Products: